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Budd-Chiari syndrome (BCS) is a rare disorder that is characterized by hepatic venous outflow
obstruction. The aim of this study was to assess determinants of survival and to evaluate the effect
of portosystemic shunting. In this international multicenter study, 237 patients with BCS,
diagnosed between 1984 and 2001, were investigated. Univariate, multivariate, and time-depen-
dent Cox regression analyses were performed. Overall survival at 1, 5, and 10 years was 82%
(95% CI, 77%–87%), 69% (95% CI, 62%–76%), and 62% (95% CI, 54%–70%), respectively.
Encephalopathy, ascites, prothrombin time, and bilirubin were independent determinants of
survival. A prognostic classification combining these factors could identify three classes of pa-
tients (classes I–III). The 5-year survival rate was 89% (95% CI, 79%–99%) for class I, 74%
(95% CI, 65%–83%) for class II, and 42% (95% CI, 28%–56%) for class III. Anticoagulants
were administered to 72%; only for patients in class I was this associated with a trend toward
improved survival (relative risk [RR], 0.14; 95% CI, 0.02–1.21). Portosystemic shunting was
performed in 49% of the patients (n  117); only for patients in class II, time-dependent analyses
suggested an improved survival (RR, 0.63; 95% CI, 0.26–1.49). In conclusion, at the time of
diagnosis, patients with BCS can be classified into good (I), intermediate (II), and poor (III)
prognostic classes, according to simple baseline clinical and laboratory parameters. Our results
suggest an improved survival after surgical portosystemic shunting for patients with an interme-
diate prognosis (class II). (HEPATOLOGY 2004;39:500–508.)
Budd-Chiari syndrome (BCS) comprises a group ofdisorders characterized by hepatic venous outflowobstruction. The site of obstruction is either in the
hepatic veins or the suprahepatic inferior vena cava.1 BCS
is a rare disorder that occurs predominantly in young
adults and affects more women than men. Overall, 5-year
survival varies from 50% to 80% in different series.2–4
Clinically, a classical triad of hepatomegaly, ascites,
and abdominal pain is found in many patients.2,5 How-
ever, the clinical course may differ markedly between pa-
tients. Some patients exhibit clinical signs of portal
hypertension, such as variceal bleeding and refractory as-
cites with relatively intact hepatic function.4,6 Others
have liver failure, including hepatic encephalopathy,
jaundice, and biochemical signs of severe hepatocellular
dysfunction, at presentation. The most important cause
of BCS in Western countries is thrombotic obstruction of
the hepatic veins.7 It is now believed that an inherited
predisposition and an acquired thrombogenic stimulus
may converge in the pathogenesis of BCS.5,8 Main treat-
ment options include the long-term use of anticoagulants,
surgical portosystemic shunting (PSS),9–11 transjugular
intrahepatic portosystemic shunting (TIPS),12 and ortho-
topic liver transplantation.13 Other treatment methods
are thrombolysis14 and percutaneous hepatic vein balloon
angioplasty.15
Abbreviations: BCS, Budd-Chiari syndrome; PSS, portosystemic shunting;
TIPS, transjugular intrahepatic portosystemic shunting; ALT, alanine aminotrans-
ferase; INR, international normalized ratio; ULN, upper limits of normal value;
RR, relative risk; CI, confidence interval.
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Several studies have been published on the cause, clin-
ical manifestations, prognosis, and interventions in
BCS.4–6,9,10,14,16–20 However, the results vary widely, and
unequivocal conclusions cannot be drawn. Little is
known about factors that may be of relevant predictive
value for the survival of BCS patients. Because of its rarity,
most studies on BCS are case reports or contain limited
numbers of patients. Small series are hampered by the lack
of sufficient statistical power to control for baseline char-
acteristics when survival or the effect of therapy is evalu-
ated. Institutional experience and preferences as well as
patient selection play a major role in the choice of treat-
ment.21 This creates a large degree of heterogeneity be-
tween study populations. Most studies on the effect of
therapeutic interventions, in particular PSS, do not report
selection criteria nor do they control for differences in
baseline characteristics between patients who do or do not
undergo PSS. Furthermore, many studies do not adjust
for the time-interval between diagnosis and the proce-
dure, which easily could lead to a response-time bias.
The aim of the present study was to identify indepen-
dent prognostic markers for survival of BCS patients and
to evaluate the effect of PSS on survival, controlled for
these prognostic markers as well as for the time-interval
between diagnosis and procedure. We conducted a large
collaborative, multicenter study in which baseline charac-
teristics of BCS patients were evaluated in multivariate
models.
Patients and Methods
Patients. Patients were derived from the computer-
ized diagnosis registration systems of all Dutch academic
hospitals, the Mayo Clinic (Rochester, MN), Hôpital
Beaujon (Clichy, France), and Hôpital Louis Mourier
(AP-HP, Colombes, France). All participating hospitals
serve as tertiary referral centers. Part of the study popula-
tion from France was described previously by Zeitoun et
al.16 and from the Mayo Clinic by Tsiotos et al.22 By
means of a standardized review of the medical charts, all
patients consecutively diagnosed with BCS between Jan-
uary 1984 and January 2001 were identified using the
following key words: Budd-Chiari syndrome, hepatic
outflow obstruction, hepatic vein thrombosis, vascular
liver disease, hepatic vein, inferior vena cava, portal vein,
and thrombosis. BCS was defined as hepatic venous out-
flow obstruction and its manifestations, regardless of the
cause and regardless of the level of the obstruction from
the small hepatic veins to the entrance of the inferior vena
cava into the right atrium.1 Hepatic outflow obstruction
caused by congestive heart disease and sinusoidal obstruc-
tion syndrome (veno-occlusive disease) were considered
separate disease entities. These patients were not included
in our study. The diagnosis of BCS was established by
Doppler ultrasound, computerized tomography, mag-
netic resonance imaging, or venography.1 Histologic or
nonspecific radiologic features suggestive of BCS were not
considered diagnostic. Date of diagnosis was defined as
the date of first evidence of BCS on radiologic imaging.
Diagnosis could be made either at the participating center
or at a smaller regional hospital before referral to the par-
ticipating center. In both cases, the first available data
were used as baseline data. Data on patient characteristics
at the time of diagnosis, type of treatment during follow-
up, and clinical outcome were collected from patient
records in structured, uniform data forms. If necessary,
patients or general physicians were approached to com-
plete follow-up data. All patients were followed up from
the date of diagnosis until death, orthotopic liver trans-
plantation, study closure (January 1, 2001), or, in case of
loss to follow-up, the date of last visit.
Clinical Assessment. The choice of variables to be
used in the analyses was based on known prognostic fac-
tors in hepatologic disorders in general and BCS in par-
ticular, as well as on clinical experience with relevant
factors.
The following characteristics, present at the time of
diagnosis, were evaluated for their prognostic signifi-
cance: age, sex, ascites, hepatomegaly, splenomegaly,
variceal hemorrhage, hepatic encephalopathy, myelopro-
liferative disorders, paroxysmal nocturnal hemoglobin-
uria, site of outflow obstruction (hepatic veins, vena cava
inferior, or combination), portal vein thrombosis, liver
cirrhosis, Child-Pugh score, prothrombin time, platelet
count, and serum levels of bilirubin, albumin, alanine
aminotransferase (ALT), alkaline phosphatase, sodium,
creatinine, and hemoglobin. Ascites, hepatomegaly, and
splenomegaly were assessed by abdominal ultrasonogra-
phy or other radiographic methods. Presence of esopha-
geal varices and variceal hemorrhage was confirmed by
radiologic or endoscopic examination. Underlying my-
eloproliferative disorders were confirmed by bone marrow
examination to include only overt forms.23 Hepatic en-
cephalopathy was evaluated by the Glasgow Coma Scale.
The Child-Pugh score was calculated for those with com-
plete data on degree of ascites and encephalopathy, the
prothrombin time, and serum levels of bilirubin and al-
bumin at the time of diagnosis (n  190).
Therapeutic interventions during follow-up were as-
sessed. For portosystemic shunting (including TIPS), the
interval between the date of diagnosis and date of shunt-
ing was determined to allow time-dependent analysis of
the effect on survival.
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Statistical Analysis. Transplantation-free survival
rates were calculated by means of the Kaplan-Meier
method. Univariate survival analyses of the effect of pa-
tient characteristics were based on comparison of survival
curves by the log-rank test, including trend analysis for
ordered variables. Statistically significant variables, as well
as other clinically relevant variables (age, site of obstruc-
tion, ALT levels) were introduced into a multivariate
Cox’s proportional hazards analysis, with stratification for
country. By means of stepwise backward elimination, a
final model was constructed comprising variables that
were significantly and independently (i.e., controlled for
other variables) related to survival. Next, these prognostic
markers were included as variables in a linear equation to
create a BCS prognostic formula, in which the logarithm
of the corresponding rate ratios (i.e., the regression coef-
ficients of the proportional hazards model) was used as a
coefficient. Accordingly, all patients were classified into
groups based on their prognostic scores, and survival
curves were compared.
Because PSS was performed during the follow-up, the
effect of portosystemic shunting on survival was analyzed
in an extended Cox’s proportional hazard model, in
which shunting was included as a time-dependent covari-
ate. This meant that at t  0, no patient had received a
PSS (all “not performed”). At the time a patient received
PSS (t  x), this variable was scored as “performed.” In
this way, the period that patients had lived up to the
moment of PSS was calculated as “nonshunted survival
period” in the Cox analysis.
For all Cox models, the assumption of proportional
hazards was investigated for each variable by studying the
ln(-ln)plot and by entering portosystemic shunting as a
time-dependent variable multiplied by the logarithm of
time. All analyses were carried out in SPSS for Windows,
version 10.1.1 (SPSS, Chicago, IL). The level of statistical
significance was set at P  .05.
Results
Two hundred eighty-two patients with the diagnosis of
BCS were identified in our institutions. Patients with he-
patic outflow obstruction resulting from malignancy (n 
35), patients with BCS after liver transplantation (n  3),
and patients diagnosed at autopsy (n  7) were excluded.
This left a total of 237 patients who were eligible for
analysis.
Patient characteristics at the time of diagnosis are
shown in Table 1. Patient inclusion per year from 1984
until 2001 showed a homogeneous distribution (mean,
14; range, 7–23). The sample included 73 Dutch, 76
American, and 88 French patients with no statistically
significant difference in survival; 5-year survival was 73%
(95% CI, 62%–84%), 61% (95% CI, 50%–72%), and
72% (95% CI, 61%–83%), respectively. Between coun-
tries, the number of idiopathic cases, the surgical inter-
vention rate, and reasons for exclusion were comparable.
Median age was 35 years (range, 13–76 years), and 67%
of the patients were female. In 54 patients (23%), an overt
myeloproliferative disorder was present, including poly-
cythemia rubra vera (n  45) and essential thrombocyto-
sis (n  9). Paroxysmal nocturnal hemoglobinuria was
present in 12 cases. Ascites (84%) and hepatomegaly
(76%) were the most prevalent clinical symptoms. Eleven
patients were asymptomatic. Median Child-Pugh score
was 8 (range, 5–14). At liver biopsy (n  138), evidence
Table 1. Patient Characteristics at the Time of Diagnosis in
237 Patients With Budd-Chiari Syndrome
Characteristic Obtained Data
Age (yrs)* 35 (13-76)
Male/female (%) 78/159 (33/67)
Myeloproliferative disorders (%) 54 (23)
Polycythemia rubra vera 45
Essential thrombocythemia 9






Variceal bleeding 19 (8)
Site of outflow obstruction (%)
Hepatic veins 147 (62)
Inferior vena cava 17 (7)
Combined hepatic veins and inferior vena cava 73 (31)
Membranous obstruction of inferior vena cava (%) 9 (4)
Portal vein obstruction 34 (14)
Serum levels
Albumin (g/L)* 34 (13-57)
Bilirubin (mol/L)* 28 (3-301)
Platelet count (10E6/L)* 265 (10-896)
ALT (ULN†)* 1.0 (0.1-86.7)
Alkaline phosphatase (ULN†)* 1.1 (0.3-16.3)
Hemoglobin (mmol/L)* 8.1 (3.5-13.0)
Sodium (mmol/L)* 137 (121-145)
Creatinin (mol/L)* 80 (35-469)
Prothrombin time: INR  2.3 (%)‡ 43 (26)
Cirrhosis at liver biopsy (%)§ 11 (8)
Child Pugh classification
Child A 45 (24)
Child B 103 (54)
Child C 42 (22)
Abbreviations: ALT, alanine aminotransferase; INR, international normalized
ratio.
*Median (range).
†ULN, Upper limits of normal value; corrected for intercenter variation in normal
values.
‡In the French sample, the Quick-time was used as a measure for the
prothrombin time. A Quick time value between 100% and 44% was assumed to
be equal to an INR 2.3. A Quick time less than 44% was equal to an INR 
2.3.
§One hundred thirty-eight patients underwent a liver biopsy.
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for cirrhosis was found for 11 patients. The hepatic out-
flow obstruction was located in the hepatic veins in 62%,
the inferior vena cava in 7%, and both in 31% of the cases.
Thirty-four patients (14%) had combined BCS and ex-
trahepatic portal vein thrombosis.
Survival. Follow-up ranged from 2 days to 203
months (median, 44 months). During follow-up, 52 pa-
tients (22%) died and 29 (12%) underwent orthotopic
liver transplantation. Twenty patients were lost to follow-
up. Causes of death were liver failure (n  17), postoper-
ative multiorgan failure (n  12), sepsis (n  4), newly
developed malignancy (n  2), cardiovascular disease
(n  3), cerebrovascular accident (n  2), variceal bleed-
ing (n  1), and combinations (n  3). For 8 patients,
information on cause of death could not be retrieved.
Survival rates were 82% (95% CI, 77%–87%), 69%
(95% CI, 62%–76%), and 62% (95% CI, 54%–70%) at
1, 5, and 10 years, respectively (Fig. 1).
Prognostic Factors. Univariate analyses showed that
ascites (P  .03), encephalopathy (P  .001), Child-
Pugh score (P  .001), prothrombin time (P  .001),
and serum levels of sodium (P  .03), creatinine (P 
.01), albumin (P  .02), and bilirubin (P  .001) were
significantly related to survival (Table 2).
These variables, as well as age, serum levels of ALT, and
site of outflow obstruction, were introduced into a mul-
tivariate Cox regression analysis, stratified by country.
Variables were selected by using a stepwise backward
elimination technique. The final Cox model showed that
encephalopathy (P  .001), ascites (P  .08), prothrom-
bin time (P  .02), and serum levels of bilirubin (P  .07)
were independent prognostic markers for survival for 205
patients with complete data on these variables (Table 3).
Several tests for interaction between these markers did
not alter the results (data not shown). In addition, adding
quadratic effects of continuous variables did not modify
the results (data not shown).
The predictors obtained from the multivariate Cox’s
analysis were included in a linear prognostic formula in
which the coefficients were equal to the regression coeffi-
cients of the proportional hazard model (Table 3). The
equation was as follows:
1.27  encephalopathy  1.04  ascites  0.72
 prothrombin time  0.004  bilirubin.
Ascites and hepatic encephalopathy were scored as present
(1) or absent (0) and prothrombin time as higher (1) or
lower (0) than 2.3 INR. Bilirubin was included as a con-
tinuous variable for which the risk increased with 0.004
per mol/L. The total score (i.e., the sum of item scores)
ranged from 0.02 to 4.03. Because the frequency distri-
bution of total scores was not homogeneous, we decided
to transform the linear equation into an index in which
the upper and lower quarters of the frequency distribution
were taken as the extremes. Consequently, three classes of
patients could be distinguished: class I represented a total
score between 0 and 1.1 (n  55), class II between 1.1 and
1.5 (n  95), and class III a total score of 1.5 and higher
(n  55). Five-year survival rates for the 205 patients with
complete data were 89% (95% CI, 79%–99%) for class I,
74% (95% CI, 65%–83%) for class II, and 42% (95%
CI, 28%–56%) for class III (Fig. 2).
Interventions. Overall, 171 patients of 237 (72%)
were treated with anticoagulants. Thirty-nine patients
(16%) were managed medically with diuretics, paracen-
tesis, or both only for control of their ascites. Peritone-
ovenous shunting (Denver/Leveen) was performed in
eight patients (3%), percutaneous transluminal angio-
plasty or stenting was performed in seven patients (3%),
and surgical thrombectomy or angioplasty was performed
in three patients (1%). One hundred seventeen patients
(49%) underwent PSS during follow-up. In all participat-
ing centers, indications for PSS were refractory ascites,
deterioration of liver function, or both. The distribution
of PSS in the different classes of the prognostic model was
as follows: 16 patients in class I (29%), 52 in class II
(55%), and 33 in class III (60%). The type of PSS was
mesocaval in 42 cases (36%), portocaval in 35 (30%),
mesoatrial in 10 (9%), mesoinnominate in 6 (5%), sple-
norenal in 4 (3%), cavoatrial in 2 (1%), and portoatrial in
1 (1%). In 17 patients (15%), a TIPS procedure was
performed. In 16 cases (14%), shunt failure occurred; this
was followed by revision in seven patients (all after TIPS
Fig. 1. Overall survival in 237 patients with Budd-Chiari syndrome.
Survival rates at 1, 5, 10, and 15 years were 82% (95% CI, 77%–87%),
69% (95% CI, 62%–76%), 62% (95% CI, 54%–70%), and 59% (95% CI,
51%–68%), respectively. *Numbers represent patients at risk at 1, 5,
10, and 15 years, respectively.
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procedure), a second surgical PSS in five patients, and
other forms of therapy in four patients. One patient re-
quired a third revision of the TIPS. Of all shunted pa-
tients, 26 died (22%) and 10 (9%) underwent orthotopic
liver transplantation, 5 of whom died. Of the nonshunted
patients, 19 (16%) died and 19 (16%) were transplanted,
2 of whom died.
Benefit of Anticoagulation and Portosystemic
Shunting. The use of anticoagulants to prevent further
development of thrombosis did not yield a significant
beneficial effect on survival in our total population (rela-
tive risk [RR], 1.05; 95% CI, 0.62–1.76). Results did not
alter when the group on anticoagulants in combination
with PSS was taken as a separate category (RR, 0.80; 95%
CI, 0.61–1.05). Subanalysis of the effect of anticoagu-
lants on survival for the three classes suggested improved
survival for patients in class I (RR, 0.14; 95% CI, 0.02–
1.21), but not for those in class II (RR, 0.88; 95%CI,
0.39–2.01) and class III (RR, 1.3; 95% CI, 0.50–3.04).
For the analyses on the efficacy of PSS, only the first
shunting procedure was taken into account. One hundred
six of the 117 shunted patients (91%) underwent a PSS
procedure within the first year of diagnosis (median, 1
month; range, 0–132 months). We performed a time-




(%) 95% CI P Value Numbers
5-Year
Survival
(%) 95% CI P Value
Age (yrs)*
35 121 69 60-78 .43
35 116 68 59-77
Sex
Male 78 66 55-77 .56
Female 159 70 62-78
Ascites
Present 199 66 59-73 .03
Absent 38 84 69-99
Hepatomegaly
Present 181 70 63-77 .76
Absent 47 65 51-79
Missing 9 § §
Splenomegaly
Present 120 63 54-72 .17
Absent 104 74 65-83
Missing 13 § §
Encephalopathy
Present 24 27 6-48 .001
Absent 213 73 66-80
Variceal bleeding
Present 19 71 49-93 .93
Absent 218 69 62-76
Site of outflow obstruction
Hepatic veins 147 63 54-72 .09
Inferior vena cava 17 56 28-84
Combined hepatic veins
and inferior vena cava 73 82 73-91
Portal vein thrombosis
Present 34 56 36-76 .42
Absent 203 71 40-78
Myeloproliferative disorder
Present 54 71 58-84 .92
Absent 183 68 61-75
Paroxysmal nocturnal
hemoglobinurea
Present 12 44 13-75 .18
Absent 225 70 63-77
NOTE. Comparison of Kaplan-Meier survival curves is based on log-rank testing.
*Cut-off points were based on the median.
†ULN, upper limits of normal value; corrected for intercenter variation in normal values.
‡In the French sample, the Quick-time was used as a measure for the prothrombin time. A Quick time value between 100% and 44% was assumed to be equal
to an INR 2.3. A Quick time lower than 44% was equal to an INR  2.3.
§Because of the small numbers in the missing category, no survival rates could be calculated.
Cirrhosis at liver biopsy
Present 11 37 5-69 .22
Absent 127 65 56-74
Missing 99 78 68-87
Albumin (g/L)*
34 117 60 50-70 .02
34 99 79 70-88
Missing 21 70 47-93
Bilirubin (mol/L)*
28 119 54 44-64 .001
28 109 82 74-90
Missing 9 § §
ALT (ULN†)*
1.0 85 66 55-77 .08
1.0 108 75 66-84
Missing 44 61 45-76
Sodium (mmol/L)*
137 113 64 55-73 .03
137 105 75 66-84
Missing 19 57 28-87
Creatinin (mol/L)*
80 119 60 50-70 .01
80 103 74 66-82
Missing 15 § §
Prothrombin time‡
INR 2.3 167 42 25-59 .001
INR 2.3 43 75 68-82
Missing 27 75 58-93
Child-Pugh classification
Class A 45 89 79-99 .001
Class B 103 67 57-77
Class C 42 45 29-61
Missing 47 74 60-88
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dependent Cox regression analysis in which, during the
follow-up, patients were switched to the shunted group at
the time of PSS. In the total population, the Cox assump-
tion for proportional hazards was evaluated by investigat-
ing the consecutive effects of shunting within 1 month
after diagnosis (n  63), shunting between 1 to 6 months
(n  39), and shunting after 6 months (n  15). As is
shown in Table 4, mortality risk increased as PSS was
performed later during follow-up. Therefore, analysis of
the effect of PSS in the overall population was not feasible.
When reevaluating the proportionality assumption for
the three different prognostic classes, only class II patients
exhibited an equal mortality risk of PSS after prolonged
follow-up. In this class, time-dependent Cox analysis
showed a tendency toward improved survival (RR, 0.63;
95% CI, 0.26–1.49), which is shown in Fig. 3.
A separate analysis assessing survival in relation to the
type of shunt showed similar results for surgical shunting
as for TIPS procedures (data not shown).
Discussion
There is a large variation in results of studies on BCS in
terms of clinical presentation, effects of therapy, and sur-
vival. Because the prevalence of BCS is only approxi-
mately 1:100,000, controlled prospective studies are
extremely difficult to perform. We carried out a multi-
center cohort study in which data were obtained using
standardized and predefined criteria. The present study
reports on 237 patients newly diagnosed with nonmalig-
nant BCS. This therefore is the largest cohort described
until now. The large sample size enabled us to perform
extensive survival analyses with control for possible con-
founding factors. Data were collected by using structured
data forms and attempts were made to retrieve missing
data on clinical outcome by contacting patients or their
physicians. An international multicenter study like the
Table 3. Results of Multivariate Cox Regression Analysis for
205 Budd-Chiari Syndrome Patients With Complete Data





Present 3.58 1.87-6.86 1.27
Absent
Ascites .08
Present 2.83 0.87-9.22 1.04
Absent
Prothrombin time .02
INR 2.3 2.05 1.13-3.70 0.72
INR 2.3
Bilirubin (mol/L)† .07 1.004 1.00-1.01 0.004
*The prognostic classification is based on these four variables. The equation is
as follows: 1.27  encephalopathy  1.04  ascites  0.72  prothrombin
time  0.004  bilirubin. The item-scores are equal to the natural logarithm of
the corresponding risk ratios.
†Bilirubin was included as a continuous variable.
Fig. 2. Survival for class I (n  55), class II (n  95), and class III
(n  55), according to the prognostic classification. Ptrend  .0001,
P
class I vs. II
 .013, Pclass II vs. III  .0001. *5-year survival rates.
Table 4. Survival in Relation to PSS (n  117), According
to the Interval Between Diagnosis and Shunting Using a Cox
Analysis Testing for Proportionality
Interval Between Diagnosis
and PSS (months) P Value Relative Risk 95% CI
1 (n  63) .83 1.07 0.57-2.00
1-6 (n  39) .002 3.05 1.53-6.09
6 (n  15) .009 4.15 1.42-12.12
Fig. 3. Survival in class II (n  95) according to PSS. At the time of
shunting, patients were censored from the non-PSS group and included
in the PSS group (t  0 is time of shunting). During the follow-up, 52
patients (55%) underwent a PSS. P values are derived from the Cox’s
time-dependent regression analysis. *5-year survival rate.
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present study could be hampered by crossnational varia-
tion in patient characteristics and institutional differences
in therapeutic interventions. However, by introducing
stratification for country in multivariate analyses, the ef-
fects of this variation as well as that of other possible
confounding factors were minimized.
In the present study, 5-year survival was 69%, which is
slightly higher than results from other series with long-
term follow-up.7,16 This could be because in recent years,
improvement in availability and techniques of diagnostic
tools has contributed to earlier recognition of BCS pa-
tients.19,24 Furthermore, most of our patients were treated
with anticoagulants, which, in addition to better identifi-
cation of underlying prothrombotic factors,22 has been
reported to contribute to the improvement in prognosis
of BCS.16
The aim of the present study was to assess prognostic
determinants of survival in BCS patients. We identified
four important factors that are independently associated
with survival: encephalopathy, ascites, prothrombin time,
and serum level of bilirubin. A prognostic classification,
based on these factors, identified three classes of patients
with good prognosis (class I; 5-year survival rate, 89%),
intermediate prognosis (class II; 5-year survival rate,
74%), and poor prognosis (class III; 5-year survival rate,
42%).
Only two other studies used multivariate analysis for
prognostic factors in BCS. The first was conducted in
France among 120 BCS patients diagnosed between 1970
and 1992.16 In that study, response of ascites to diuretics,
the Child-Pugh score, age, and serum creatinine seemed
to be of significant value for the prognosis of BCS. A
prognostic index based on these factors dichotomized 85
patients into a good prognostic group (5-year survival,
95%) and a poor prognostic group (5-year survival, 62%),
whereas overall 5-year survival was only 65%. In the sec-
ond study, these results were evaluated in an independent
sample of 69 patients.25 The original index was extended
with an additional factor, representing acute, chronic, or
acute-on-chronic BCS. However, a recent review of an
expert panel on BCS has stated that at the present time, no
consensus has been reached on the classification into acute
and chronic disease, because scientific arguments for this
classification are still lacking.1 Both prognostic studies
also assessed the effect of PSS and did not show a benefi-
cial effect on survival, even after control for prognostic
class.
In comparison with these previous prognostic studies,
the current study further optimizes prognostic modeling
for BCS in several ways. First, our study includes a larger
population of 237 patients, enabling analyses with more
statistical power. In addition, it allowed the identification
of three distinct prognostic groups, including a group
with a considerably poor prognosis (class III; 5-year sur-
vival, 42%), for which liver transplantation may be the
only life-saving procedure. Second, our study involves
recently diagnosed patients (between 1984 and 2001)
who were treated according to current therapeutic stan-
dards. Both previous studies did not evaluate the effect of
TIPS, because only surgical shunting procedures were in-
vestigated. In our study, 17 patients underwent a TIPS
procedure. Results of comparative analyses revealed no
effect of type of shunting on survival. Other recent studies
have demonstrated positive results of this new approach
in terms of short-term survival.12,13,26 TIPS is less invasive
and therefore probably associated with a lower procedural
mortality than PSS.27 Long-term follow-up studies are
needed to assess the place of TIPS in the treatment of
BCS. Third, our prognostic classification includes simple
clinical parameters that are easily available at diagnosis. In
contrast, both previous classifications include response of
ascites to treatment, thereby precluding its use at the time
of diagnosis. Comparison of our index, using baseline
variables only, with the previous index including a time-
and treatment-dependent ascites score, therefore was not
feasible. Fourth, the previous studies did not evaluate the
effect of PSS in a time-dependent analysis. As is indicated
by our results, the effect of shunting may not be equal over
time, and appropriate control for this factor is needed to
avoid response-time bias. In our time-dependent analysis,
we found for class II a trend toward improved survival in
patients with a PSS as compared with patients who were
treated otherwise (RR, 0.63; 95% CI, 0.26–1.49). In
fact, this class represented the largest subgroup (n  95).
These results suggest that for a reasonable group of pa-
tients, PSS may be an effective treatment. Other studies,
mostly case series from surgical units, report on high sur-
vival rates after PSS with 5-year survival of 57%11 to
94%.9,10 However, most of these studies do not provide
data on patient selection criteria, which play a major role
in the long-term results of treatment,21 nor do they take
account of differences in time-point of shunting within
the clinical course of patients.
Another well-known and widely used classification in
liver diseases is the Child-Pugh score. Our prognostic
classification, including encephalopathy, ascites, pro-
thrombin time, and bilirubin, but not albumin, closely
resembles this score. However, addition of albumin to this
model showed that albumin did not have a significant
impact on survival (data not shown). In addition, discrim-
inative analyses (using the Akaike information criteria)
demonstrated that our prognostic model was superior to
the Child-Pugh score in predicting the outcome in pa-
tients with BCS (data not shown).
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It is known that in BCS, a variety of histopathologic
features can be found, ranging from centrilobular conges-
tion and necrosis to venoportal or venocentric cirrhosis.28
However, the prognostic role of histologic examination is
probably limited. Previously, no significant association
was found between findings at histologic examination and
survival in 45 BCS patients.3 This can be explained partly
by the expected inhomogeneous distribution of liver cell
lesions, which may lead to sampling errors of biopsy spec-
imens. Histopathologic findings also were not predictive
for early or late shunt patency and survival among patients
undergoing PSS.22 In this study, hepatocellular function
and the time between onset of clinical symptoms and
diagnosis, rather than results of histologic analysis, were
suggested to be the crucial factors in choice of therapy.
Given its relatively low predictive value and the fact that
only limited numbers of liver biopsies have been per-
formed at the time of diagnosis, the prognostic value of
histologic analysis was not assessed in the present study.
Although a large randomized study has never been per-
formed, nearly all studies suggest that the administration
of anticoagulants will prevent extension of thrombosis
and may induce recanalization.4,24,29 In our study, most
patients (72%) received anticoagulants. Overall, we could
not detect a significant effect on survival when we com-
pared patients treated with or without anticoagulants.
Only for patients in class I was there a trend toward im-
proved survival (RR, 0.14; 95% CI, 0.02–1.21). Because
the reason to withhold anticoagulants often was un-
known, this result should be interpreted with caution.
As others have stressed, orthotopic liver transplanta-
tion is an effective salvage procedure in the cases of acute
fulminant or end-stage liver failure.30–32 Without trans-
plantation, these patients most likely would have had a
poor outcome. For this reason, we have used transplanta-
tion-free survival as the outcome measure. Because the
decision to perform liver transplantation might have been
based on variables from our prognostic classification, we
assessed whether our results would alter if only death was
considered as endpoint. For this analysis, patients who
received a liver transplantation (n  29) were censored at
time of intervention. We found that our prognostic clas-
sification remained a valuable tool to predict real survival
(P  .001).
In conclusion, major prognostic factors for BCS are
prothrombin time, serum bilirubin levels, and the pres-
ence of hepatic encephalopathy and ascites. A prognostic
classification combining these factors divides patients into
three groups with a good (class I), intermediate (class II),
or poor (class III) prognosis. This classification, based on
simple clinical and laboratory parameters, is a useful tool
for assessment of disease severity at the time the diagnosis
of BCS is established and before any form of therapy has
been instituted. After adjustment for the time-interval
between diagnosis and PSS, a trend toward improved sur-
vival was found for class II patients undergoing PSS.
These results suggest that, in contrast to findings from
other studies, shunting may well be valuable for a large
subgroup of patients. Prospective studies are needed to
confirm these results and to evaluate the effect of deriva-
tive therapy further in patients with BCS.
Acknowledgment: The authors thank other investiga-
tors who participated in this study: T.J. Tang (Erasmus
Medical Center, Rotterdam), W.C.J. Hop (Erasmus
Medical Center, Rotterdam), J. Meinardi (University
Hospital, Groningen), S.H. van Uum (University Hospi-
tal St. Radboud-Nijmegen, currently University Hospital
Saskatoon), R.A.F.M. Chamuleau (Academic Medical
Center, Amsterdam), C.M.J. van Nieuwkerk (Free Uni-
versity, Amsterdam), S. Escolano (Groupe Hospitalier
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